{"ts": 1769396022.219229, "content": "Pipeline PharmAbcine has focused on the development of novel antibody therapeutics since the company\u2019s foundation in 2008 and laid the groundwork for the commercialization of olinvacimab, PMC-309, PMC-403, and PMC-402. We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s Image map Image map Image map Image map Core Pipeline Olinvacimab ( TTAC-0001) Angiogenesis Inhibitor VEGFR2 Clinical mAb More New Candidates PMC-005BL New Candidates EGFRvIII Preclinical/Optimization ADC/CAR-T/RIT Soon PMC-901 New Candidates VEGF-A Preclinical Biosimilar Soon PMC-309 Immune checkpoint inhibitor VISTA Preclinical mAb More \uc2e0\uc0dd\ud6c4\ubcf4\ubb3c\uc9c8 PMC-122 New Candidates PD-L1xCD47 Preclinical/Optimization Bispecific Ab Soon PMC-902 New Candidates VEGF/PIGF Preclinical Biosimilar Soon PMC-402 Immune Activator TIE2 Preclinical mAb More \uc2e0\uc0dd\ud6c4\ubcf4\ubb3c\uc9c8 PMC-401 New Candidates ANG2 Preclinical mAb Soon Core Technology Fully Human Antibody Library Antibody Development Antibody Engineering > More Link PMC-403 Vessel-normalizer TIE2 Preclinical mAb More \uc2e0\uc0dd\ud6c4\ubcf4\ubb3c\uc9c8 PMC-401s New Candidates ANG2 Preclinical/Optimization mAb Soon Olinvacimab PMC-309 PMC-402 PMC-403 LinkedIn I Facebook I YouTube 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea HQ +82-42-863-2017 R&D Center +82-42-861-2017 FAX +82-42-863-2080 COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.", "type": "text"}